An important consideration in studies that use cause-specific endpoints such as cancer-specific survival or disease recurrence is that risk of dying from another cause before experiencing the event of interest is generally much higher in older patients. Such competing events are of major importance in the design and analysis of studies with older patients, as a patient who dies from another cause before the event of interest cannot reach the endpoint. In this Commentary, we present several clinical examples of research questions in a population-based cohort of older breast cancer patients with a high frequency of competing events and discuss implications of choosing models that deal with competing risks in different ways. We show that in populations with high frequency of competing events, it is important to consider which method is most appropriate to estimate cause-specific endpoints. We demonstrate that when calculating absolute cause-specific risks the Kaplan-Meier method overestimates risk of the event of interest and that the cumulative incidence competing risks (CICR) method, which takes competing risks into account, should be used instead. Two approaches are commonly used to model the association between prognostic factors and cause-specific survival: the Cox proportional hazards model and the Fine and Gray model. We discuss both models and show that in etiologic research the Cox Proportional Hazards model is recommended, while in predictive research the Fine and Gray model is often more appropriate. In conclusion, in studies with cause-specific endpoints in populations with a high frequency of competing events, researchers should carefully choose the most appropriate statistical method to prevent incorrect interpretation of results.
In order to study treatment efficacy or other outcomes in clinical research, large cohorts of patients are often followed during a certain period of time. Frequently, cause-specific endpoints are used in these studies, such as recurrence, cancer-specific mortality, or cardiovascular mortality (1) . For these endpoints, statistical methods that assess the time to an event such as the Kaplan-Meier method or the Cox Proportional Hazards model are frequently used (2, 3 ).
An important consideration in studies that use these causespecific endpoints is that the risk of dying from a cause other than reaching the endpoint of interest is generally much higher in older patients than in younger patients (4, 5) . These so-called competing events are of major importance in the design and analyses of studies with older patients (5) because a patient who dies from another cause can obviously not reach the endpoint of interest anymore. This topic is especially important in geriatric oncology research as a large proportion of older cancer patients will die from non-cancer-related causes before reaching the endpoint of interest (5) . For example, around 70% of breast cancer patients age 75 years or older who die do not die from breast cancer but from another cause (6) .
There are several statistical methods that are frequently used for time-to-event analyses such as the Cox Proportional Hazards Model and the Fine and Gray model. These methods deal with competing events in different ways (2) . It is likely that the choice of model can strongly influence the interpretation of the outcome, especially in populations with a high frequency of competing events (3, 4) . Several studies have described the methodology of dealing with competing risks in detail, but these methodological papers may be difficult to interpret in clinical research. Therefore, the aim of this study is to present clinical examples of research questions in a population-based cohort of older breast cancer patients with a high frequency of competing events and to discuss the implications of choosing different methods for the interpretation of the results. In addition, this paper will give recommendations for choosing specific statistical methods for specific research questions.
Theoretical Framework
First, we will provide some background information on methods that can be used to calculate absolute risks (ie, cumulative incidences), and models that can be used to model the effect of variables on the outcome.
Estimating Absolute Risks
The Kaplan-Meier method is a commonly used method to estimate survival probabilities over time. It can deal with censored follow-up times; ie, it can handle situations where the exact time of death is not known because patients drop out of the study or are still alive at the end of follow-up. One important assumption of the Kaplan-Meier method is independent censoring: At any time patients with censored survival times have the same survival prognosis as patients who are still in the study (7) .
Kaplan-Meier curves are often used to calculate survival probabilities for a specific cause of death. Patients who die of other causes are censored. Clearly, the assumption that censored patients have the same prognosis as those who are still followed is invalid because patients who die of other causes have a probability of zero to reach the cause of interest. This means that estimated survival probabilities of the Kaplan-Meier method are no longer correct. Hence, the Kaplan-Meier method does not estimate the actual survival probability but estimates what would have been observed if dying from other causes would not have been possible.
Alternatively, the Cumulative Incidence Competing Risks (CICR) method (2,3) assumes that patients who experienced a competing event are no longer at risk for the endpoint of interest (8) .This approach estimates the actual probabilities of reaching different endpoints (cumulative incidences). At each time point, the sum of all the cumulative incidences will be equal to the total probability to reach an endpoint before that time.
To illustrate the difference between the two methods, consider a very simple example in which three women with breast cancer are followed. One woman dies after one month of a myocardial infarct (MI), the second woman dies after two months of breast cancer, and the third woman is still alive after three months. The Kaplan-Meier method will estimate the probability to die of a MI within three months as 1/3. However, when considering death because of breast cancer, the Kaplan-Meier method treats the women who died in the first month of MI as censored after month 1, meaning that there are only two women at risk at month 2. The risk of dying of breast cancer in month 2 is therefore estimated as being 1/2. The three-month probability to die of breast cancer is then estimated as being 1/2, the probability to die of MI as 1/3, and the probability to be alive after three months as only 1/6. This clearly shows that the Kaplan-Meier method yields incorrect results. The CICR method accounts for the woman with the competing event by adding her to the denominator of the probability to die of breast cancer. This yields a three-month probability to die of breast cancer of 1/3, the probability to die of MI is 1/3, and the probability to be alive is 1/3.
Hazard Functions
There are different ways to assess the association between certain variables and the outcome with the possibility to adjust for confounding factors. The most commonly used methods are Cox proportional hazards models and Fine and Gray models. In order to understand the difference between these two models, we first have to introduce the concept of the hazard function. Roughly speaking, hazard functions are event rates that vary over time. An intuitive explanation of the hazard can be given in the situation when time is discrete. In this instance, the hazard at a certain time is the probability to die at that time point in those patients who are still alive (2) . In absence of competing risk, there is a 1:1 mathematical relation between the hazard function and the survival function.
Cox Proportional Hazards Model
The Cox proportional hazards model assesses the effects of variables on the hazard function. In the Cox proportional hazards model, hazard functions for different values of the prognostic variable are assumed to be proportional over time, and the parameters of the models can be interpreted as hazard ratios (HRs). In absence of competing risk, a hazard ratio above 1 implies smaller survival probabilities for the exposed group compared with the unexposed group.
In a similar way, cause-specific hazard functions can be defined. Cause-specific hazards are similar to cause-specific mortality rates over small time periods. Effects of prognostic factors on cause-specific hazards can be assessed using the Cox proportional hazards model, where subjects who die of other causes are censored. However, a hazard ratio above 1 no longer implies that subjects with the risk factor are truly more likely to experience the specific event because subjects can die of other causes before they are able to reach this event. If the hazards for dying from other causes are much larger and the prognostic factor also affects these hazards, it could happen that actually fewer people reach the cause of interest. For example, smoking increases the hazard to develop dementia, but only few smokers will actually develop dementia because of the competing effects of death because of cancer or cardiovascular diseases. As a result, it could happen that actually fewer smokers than nonsmokers will experience dementia (ie, the cumulative incidence of dementia is lower in the smoking group), even though the cause-specific hazard ratio for the effect of smoking on dementia may actually be larger than 1. Assuming that there is a biological relation between smoking and dementia, this relation can be found by the Cox regression model (ie, the HR is higher than 1 for smokers) while the cumulative incidence of dementia is in fact lower in smokers because of competing causes of death.
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Fine and Gray Model
The Fine and Gray model (9) links the effect of risk factors directly to the cause-specific cumulative incidences of death. In our smoking/dementia example, the Fine and Gray model considers the direct effect of smoking on the cumulative incidence of dementia (which was lower for smokers because of the competing risks). The effects of risk factors are expressed in subdistribution hazard ratios (SHR), where the subdistribution hazard function has a 1:1 relation with the cause-specific cumulative distribution function. An intuitive interpretation of this SHR is difficult, but readers should be reminded that an SHR above 1 corresponds to higher cause-specific event probabilities. In our dementia example, the Fine and Gray model will yield an SHR below 1 as it directly models the cumulative incidence of developing dementia in both subgroups, resulting in a lower risk of dementia for smokers. For a more detailed theoretical background of these models, we refer to Putter et al. (3) .
Clinical Examples
For the examples in this Commentary, we used data from the population-based Female breast cancer in the elderly; Optimizing Clinical guidelines USing clinico-pathological & molecular data (FOCUS) cohort. This cohort comprises all incident breast cancer patients age 65 years or older who were diagnosed in the geographically defined Comprehensive Cancer Center Region West in the Netherlands between January 1997 and December 2004 (n = 3672). Trained personnel reviewed the charts of these patients and collected information on specific treatments, comorbidity according to the ICD-10 classification (10), adverse events, recurrences, and geriatric parameters including polypharmacy, difficulties walking, poor vision and hearing, and living in a nursing home (11) .
For the examples that are used below, only patients with nonmetastatic invasive breast cancer who received primary surgery were included. The endpoint of interest was breast cancer recurrence, defined as any local recurrence (skin or in-breast), regional recurrence (axillary or supraclavicular lymph nodes), or distant metastasis. The competing event was defined as death because of any cause without breast cancer recurrence. Censoring only occurred because of end of follow-up or emigration, the latter being very rare in our cohort.
Overall, 2805 patients were included in the analyses. Patient and tumor characteristics are briefly described in Table 1 . Median follow-up time was 5.6 years, ranging from 0 to 14.2 years. Overall, 478 (17%) developed a breast cancer recurrence. The prevalence of competing events (death without recurrence) was 36% (n = 1015). The risk of competing events increased with age, from 19% in patients younger than age 75 years to 54% in patients age 75 years or older.
Example 1: Psychiatric Disorders in Association With Breast Cancer Recurrence
Recently, we assessed the association between concomitant disease and breast cancer recurrence (11) as it has been suggested that concomitant diseases can interact with tumor growth and treatment (12) . Hence, the research question that we aimed to study was of an etiological nature. One of the concomitant diseases that we assessed was psychiatric disorders, defined according to the ICD10-classification (10). We will now discuss several models that can be used to study the association between psychiatric disease and breast cancer recurrence. For simplicity, we will present univariate analyses only.
Overall, 256 patients in the FOCUS cohort had a psychiatric disorder. Of all patients with a psychiatric disorder, 29 (11%) developed a breast cancer recurrence during follow-up. Among the 2549 patients without psychiatric disorders, 449 (18%) developed a recurrence. Among patients with psychiatric disorders, 150 (59%) competing events occurred, as compared with 865 (34%) among patients without psychiatric disorders.
First, we assessed the association of psychiatric disease with breast cancer recurrence using the Kaplan-Meier method. The 10-year cumulative incidence of breast cancer recurrence as calculated by the Kaplan-Meier method in patients without * CI = confidence interval; CICR = cumulative incidence competing risks; HR = hazard ratio; KM = Kaplan-Meier; SHR = subdistribution hazard ratio.
a psychiatric disorder was 24%, compared with 18% among patients with a psychiatric disorder (Table 2) . Second, we used the CICR method to assess cumulative incidence of recurrence, which resulted in a 10-year cumulative incidence of recurrence of 20% and 12%, respectively, for patients without and with a psychiatric disorder. This shows that the Kaplan-Meier method overestimates the cumulative incidences. As shown in Table 2 , the hazard ratio for having a recurrence for patients with a psychiatric disorder was 0.78 (95% confidence interval [CI] = 0.53 to 1.13) compared with patients without a psychiatric disorder, calculated by unadjusted Cox regression analysis. This implies that there is no statistical difference in the hazard on recurrences between patients with and without psychiatric disorders. The hazards were proportional over time (tested using Schoenfeld residuals, P = .27).
Patients with a psychiatric disorder had a higher probability to die of any cause (HR = 1.6, 95% CI = 1.4 to 1.8, P < .001, compared with patients without psychiatric diseases). In Fine and Gray regression analysis, the SHR was 0.61 (95% CI = 0.42 to 0.90) for patients with a psychiatric disorder, as compared with patients without psychiatric disorders. This implies that the probability of recurrence was estimated to be lower for patients with psychiatric disease when the Fine and Gray model was used compared with the Cox Regression Model. In this example, the Fine and Gray model, in contrast with the Cox model, even yielded a statistically significant result.
Example 2: Prediction of Breast Cancer Recurrence in Older Patients
Currently, interest is in the prediction of the risk of breast cancer recurrence and breast cancer mortality in order to estimate which patients are at high risk and should receive additional treatments. Most currently available models were developed in generally young populations and were not validated in older populations (13) . We recently showed that the online Adjuvant! program, which is widely implemented in daily clinical practice, does not accurately predict breast cancer recurrence in older patients (14) . Therefore, one of the aims of the FOCUS study was to develop a new prediction tool that can be used to estimate breast cancer recurrence in older patients. Hence, for this study, we were interested in predictors of breast cancer recurrence and in calculating the absolute risk of recurrence.
Ten-year cumulative incidences of recurrence and competing events, calculated by the Kaplan-Meier method and the CICR function, are presented in Figure 1 , A and B, respectively. As shown in Figure 1A , towards the end of follow-up the probability of dying without breast cancer recurrence and the cumulative incidence of recurrence as calculated by the Kaplan-Meier method added up to an estimate higher than the cumulative incidence of death or recurrence combined. In contrast, the sum of the estimates of mortality and recurrence was equal to the cumulative incidence of death or recurrence combined when the CICR method was used ( Figure 1B) . Clearly, the Kaplan-Meier method overestimated the cumulative incidence of recurrence and the cumulative incidence of competing events.
In a recent review, it was shown that both tumor size and nodal status are the most incorporated variables in prediction models for breast cancer prognosis (13) . Therefore, for this example we assessed the predictive value of tumor stage according to the Tumor-Node-Metastasis (TNM) classification (15) . In order to further demonstrate the impact of competing events, we stratified patients into two age groups: younger than age 75 years and (Table 3 ). In both age groups, tumor stage was predictive for breast cancer recurrence, as can be expected. However, in patients younger than age 75 years, the prevalence of competing events was 19% during follow-up, which is much lower than in patients age 75 years or older, of whom 54% of all patients died without a recurrence. Among patients younger than age 75 years, the lower incidence of competing events, as compared with patients age 75 years or older, resulted in relatively small differences in outcomes between the Kaplan-Meier method and the CICR method, while in the patients age 75 years or older the KaplanMeier method more strongly overestimated the risk of recurrence. Cox Regression analyses resulted in a strongly increased risk of recurrence with increasing tumor stage (HR = 5.42, 95% CI = 4.08 to 7.21 for stage III vs stage I) ( Table 3 ). Although the difference between the tumor stages remained statistically significant in the Fine and Gray analysis, the Fine and Gray analysis attenuated the effect estimates. For predictive research, we are interested in the direct effect on the cumulative incidence, and therefore Fine and Gray analyses provide more valid effect estimates. As shown in Table 3 , the differences between estimates that are calculated in Cox Regression analyses and Fine and Gray analyses become larger when the frequency of competing events increases.
Discussion
Our results show that in populations with a high frequency of competing events, it is important to consider which methods are the most appropriate to deal with cause-specific endpoints. The Kaplan-Meier method should never be used to estimate cause-specific survival curves because it overestimates the absolute risk of the event of interest. The CICR method appropriately deals with competing risks. When assessing relative effect sizes in etiologic research, the Cox proportional hazards model is most appropriate. In contrast, to estimate effects on the absolute risk in predictive research, the Fine & Gray Model should be used in populations with a high frequency of competing events.
The main strength of this Commentary is that the examples were performed using a real cohort of patients with a high prevalence of competing risk. By presenting the results of several methods in different research questions, we were able to demonstrate the effects of the choice of a certain method in different settings. Of course, this study also has its limitations. First, it must be noted that the recurrence rate that was registered in the cohort may have been underestimated as older patients may be less adherent to follow-up schemes. This may have influenced our analyses, especially if there was selective nonadherence to follow-up schemes. In addition, 10-year follow-up for recurrence was not complete for the whole cohort, but this mostly applied to the most recent years of the cohort, and it is unlikely that this has influenced our results as it has been shown that outcome of older patients has not changed in recent years (16) .
With the results of our current study, we want to highlight the difference between etiological and predictive research questions in the comparison between the Cox proportional hazards model and the Fine and Gray model. In Example 1, the Fine and Gray model yielded rather strange results from an etiologic point of view as it suggests that psychiatric disorders are protective for recurrence. It is very unlikely that there is some biological mechanism in which psychiatric disorders are protective for breast cancer recurrence. More likely, our finding can be explained by the fact that the Fine and Gray analysis incorporates the competing risk of death, which influences the cumulative incidences of recurrence. This makes sense because patients with psychiatric disorders (especially dementia) have an increased risk of dying compared with patients without psychiatric disorders and patients who have died cannot get a breast cancer recurrence anymore. In contrast, the Cox regression model considers the effect on the cause-specific hazards, ie, on the instantaneous risk of recurrence for patients who are still at risk for the event at a certain time point, which is what interested us in this research question.
Therefore, in etiologic research questions, the Cox regression model is often the most appropriate method. In contrast, for predictive studies, methods that incorporate competing events such as Fine and Gray competing risk regression are more appealing because they provide a single summary value for the association between a risk variable and the cumulative cause-specific risk. In this case, it is important to consider that patients with a large risk of experiencing a competing event are unlikely to develop a breast cancer recurrence. Note that in this Commentary we focused on the choice of the appropriate measures for the effect of risk factors on breast cancer recurrence. Estimates of absolute mortality probabilities for specific causes as functions of risk variables can be obtained from either of the two models. For the Cox model approach, this implies estimating the causespecific hazard ratios and using the Aalen-Johansen estimator to get the cumulative incidences, a direct extension of the CICR method, which can be carried out in, for example, the R packages mstate and survival (3, 17, 18) . A major advantage of this Cox model approach is that it ensures that the sum of the cause-specific cumulative incidence equals the total cumulative incidence of experiencing any of the endpoints. This is not guaranteed when calculating cumulative incidences using Fine and Gray models. Another statistical argument in favor of modeling the cause-specific hazards using Cox models is that the proportional hazard assumption is often not unreasonable and can straightforwardly be checked. The proportional sub distribution hazard assumption in the Fine and Gray model is unlikely to hold over longer time periods. Moreover, the proportional subdistribution hazard assumptions of the Fine and Gray model will generally not hold for each of the different endpoints, and using Fine and Gray models to calculate absolute mortality probabilities could therefore yield impossible results (19, 20) . Hence, the Fine and Gray model does have some major limitations that should be taken into account. These issues that we highlight are especially important for studies in older patients with indolent cancer types such as prostate cancer or hormone receptor-positive breast cancer as the risk of competing mortality is generally large in these studies, especially in studies that require a long period of follow-up (eg, adjuvant studies). In addition, the issue of competing mortality should be considered in other populations with a large frequency of competing events as well, such as populations with many concomitant diseases or a limited performance status, even if these are not limited to older patients. In contrast, the issue of competing mortality does not play a major role in studies that investigate older populations with highly aggressive tumors such as pancreas cancer or lung cancer as the risk of dying from the cancer itself is high in these populations, such that cancer-specific mortality will be almost similar to overall survival. This also applies to studies in the metastatic setting as patients with metastatic disease have a large risk of dying from cancer and follow-up is generally short.
In conclusion, in studies with cause-specific endpoints in populations with a high frequency of competing events, researchers should carefully choose the most appropriate statistical method in order to prevent incorrect interpretation of study results.
